IBDEI2JG ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40533,1,4,0)
 ;;=4^R63.3
 ;;^UTILITY(U,$J,358.3,40533,2)
 ;;=^5019541
 ;;^UTILITY(U,$J,358.3,40534,0)
 ;;=R63.4^^152^2012^33
 ;;^UTILITY(U,$J,358.3,40534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40534,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,40534,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,40534,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,40535,0)
 ;;=R63.5^^152^2012^32
 ;;^UTILITY(U,$J,358.3,40535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40535,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,40535,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,40535,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,40536,0)
 ;;=R64.^^152^2012^50
 ;;^UTILITY(U,$J,358.3,40536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40536,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,40536,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,40536,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,40537,0)
 ;;=R68.3^^152^2012^55
 ;;^UTILITY(U,$J,358.3,40537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40537,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,40537,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,40537,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,40538,0)
 ;;=R73.01^^152^2012^94
 ;;^UTILITY(U,$J,358.3,40538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40538,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,40538,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,40538,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,40539,0)
 ;;=R73.02^^152^2012^95
 ;;^UTILITY(U,$J,358.3,40539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40539,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,40539,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,40539,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,40540,0)
 ;;=R73.09^^152^2012^18
 ;;^UTILITY(U,$J,358.3,40540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40540,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,40540,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,40540,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,40541,0)
 ;;=R73.9^^152^2012^89
 ;;^UTILITY(U,$J,358.3,40541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40541,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,40541,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,40541,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,40542,0)
 ;;=R76.11^^152^2012^147
 ;;^UTILITY(U,$J,358.3,40542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40542,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,40542,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,40542,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,40543,0)
 ;;=R79.1^^152^2012^3
 ;;^UTILITY(U,$J,358.3,40543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40543,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,40543,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,40543,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,40544,0)
 ;;=R82.5^^152^2012^74
 ;;^UTILITY(U,$J,358.3,40544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40544,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,40544,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,40544,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,40545,0)
 ;;=R82.6^^152^2012^30
 ;;^UTILITY(U,$J,358.3,40545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40545,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,40545,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,40545,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,40546,0)
 ;;=R82.90^^152^2012^29
